Page 8 - John Grabenstein News Today : Breaking News, Live Updates & Top Stories | Vimarsana

USA TODAY To prove their COVID-19 vaccines worked, companies had to enroll more than 100,000 participants in monthslong clinical trials. Next time, Peter Gilbert wants such tests to require only a few hundred people and eight weeks' time. To get there, Gilbert and others have to figure out how much protection people need to avoid hospitalization and death from COVID-19, or even to prevent getting infected at all. But 15 months after COVID-19 shut down most of the world, it's still not clear what level of immune protection is enough. "I haven't seen people tossing around a number, and I'm a li...

. (Tribune News Service) — To prove their COVID-19 vaccines worked, companies had to enroll more than 100,000 participants in monthslong clinical trials. Next time, Peter Gilbert wants such tests to require only a few hundred people and eight weeks' time. To get there, Gilbert and others have to figure out how much protection people need to avoid hospitalization and death from COVID-19, or even to prevent getting infected at all. But 15 months after COVID-19 shut down most of the world, it's still not clear what level of immune protection is enough. "I haven't seen people tossing around...

What level of antibodies protect against COVID-19? Researchers are rushing to find out Elizabeth Weise, USA TODAY Replay Video UP NEXT To prove their COVID-19 vaccines worked, companies had to enroll more than 100,000 participants in monthslong clinical trials. Next time, Peter Gilbert wants such tests to require only a few hundred people and eight weeks' time. To get there, Gilbert and others have to figure out how much protection people need to avoid hospitalization and death from COVID-19, or even to prevent getting infected at all. But 15 months after COVID-19 shut down m...

AstraZeneca: FDA wants more data on vaccine Erika Edwards © Provided by NBC News The Food and Drug Administration has asked AstraZeneca for a large amount of extra data related to its Covid-19 vaccine, further delaying the company's application for an emergency use authorization, or EUA, in the United States, according to a letter from the company obtained by NBC News. AstraZeneca sent the letter, dated April 21, to U.S. clinical trial investigators. It reads, in part, "This is a complex submission that includes data from studies conducted outside the U.S., as well as emergi...

The Atlantic The mRNA Vaccines Are Looking Better and Better Concerns about blood clots with Johnson & Johnson underscore just how lucky Americans are to have the Pfizer and Moderna shots. Katie Martin / The Atlantic A year ago, when the United States decided to go big on vaccines, it bet on nearly every horse, investing in a spectrum of technologies. The safest bets, in a way, repurposed the technology behind existing vaccines, such as protein-based ones for tetanus or hepatitis B. The medium bets were on vaccines made by Johnson & Johnson and AstraZeneca, which use adenovirus vectors, a tec...